KRAS and non-small cell lung carcinoma: Nevertheless, single gene alterations, such as TP53, might be positively associated with PD‐L1 expression and immune‐related genes expression, but single gene alteration alone was not able to distinguish responders from receiving ICI treatments in NSCLC; however, patients with TP53/KRAS co‐mutations were reported to be sensitive to ICI treatments, suggesting the necessity for implementation of a model combining multiple genes.19